Literature DB >> 3197706

Screening and characterization of antiepileptic drugs with rapidly recurring hippocampal seizures in rats.

E W Lothman1, R A Salerno, J B Perlin, D L Kaiser.   

Abstract

A method to efficiently screen antiepileptic drugs (AED) for their actions against complex partial and secondarily generalized seizures is presented. The procedure relies on rapidly recurring hippocampal seizures (RRHS) in rats which are first used to bring epileptic responses to a stable, fully kindled state and then to test 3 parameters--behavioral seizures, electrographic seizures, and afterdischarge thresholds--before and after drug administration. With the methods described, the effects of a given drug treatment can be thoroughly determined in a single study period. Quantitative determinations of dose-response, time-action and relative potency characteristics are readily ascertained. A battery of known AED, encompassing those in common clinical use, was studied with this system. Kindled motor seizures (classes 4 and 5) were more readily suppressed than limbic behavioral seizures (classes 1-3). Electrographic seizures were usually, but not always, shortened concurrently with suppression of behavioral seizures. Under the conditions of this study, afterdischarge thresholds were not elevated, indicating that a critical role of AED is to counteract seizure spread and prolongation. The overall behavior of the RRHS test system with AED was identical to that with traditional amygdala kindled seizures and results were in good agreement with the clinical responsiveness of the kinds of seizures that these experimental systems model. The features of RRHS make it a useful system for screening new agents for antiepileptic effects, even in circumstances where little or no information about the drug under study is available.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3197706     DOI: 10.1016/0920-1211(88)90048-4

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  11 in total

1.  Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).

Authors:  David F McComsey; Virginia L Smith-Swintosky; Michael H Parker; Douglas E Brenneman; Ewa Malatynska; H Steve White; Brian D Klein; Karen S Wilcox; Michael E Milewski; Mark Herb; Michael F A Finley; Yi Liu; Mary Lou Lubin; Ning Qin; Allen B Reitz; Bruce E Maryanoff
Journal:  J Med Chem       Date:  2013-11-11       Impact factor: 7.446

Review 2.  Key factors in the discovery and development of new antiepileptic drugs.

Authors:  Meir Bialer; H Steve White
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

3.  A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage.

Authors:  H Steve White; Anitha B Alex; Amanda Pollock; Naama Hen; Tawfeeq Shekh-Ahmad; Karen S Wilcox; John H McDonough; James P Stables; Dan Kaufmann; Boris Yagen; Meir Bialer
Journal:  Epilepsia       Date:  2011-12-09       Impact factor: 5.864

4.  Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents.

Authors:  Nina Isoherranen; Boris Yagen; José H Woodhead; Ofer Spiegelstein; Simcha Blotnik; Karen S Wilcox; Richard H Finnell; Gregory D Bennett; H Steve White; Meir Bialer
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

5.  Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property.

Authors:  Guy A Higgins; Nathalie Breysse; Elijus Undzys; D Richard Derksen; Melanie Jeffrey; Brian W Scott; Tao Xin; Corinne Roucard; Karine Bressand; Antoine Depaulis; W M Burnham
Journal:  Psychopharmacology (Berl)       Date:  2009-10-16       Impact factor: 4.530

6.  Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.

Authors:  Nina Isoherranen; H Steve White; Brian D Klein; Michael Roeder; José H Woodhead; Volker Schurig; Boris Yagen; Meir Bialer
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

7.  Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity.

Authors:  Dilip K Tosh; Silvia Paoletta; Francesca Deflorian; Khai Phan; Steven M Moss; Zhan-Guo Gao; Xiaohui Jiang; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2012-09-10       Impact factor: 7.446

8.  Neuronal Injury, Gliosis, and Glial Proliferation in Two Models of Temporal Lobe Epilepsy.

Authors:  Jaycie L Loewen; Melissa L Barker-Haliski; E Jill Dahle; H Steve White; Karen S Wilcox
Journal:  J Neuropathol Exp Neurol       Date:  2016-03-04       Impact factor: 3.685

9.  Small-molecule anticonvulsant agents with potent in vitro neuroprotection and favorable drug-like properties.

Authors:  Garry R Smith; Douglas E Brenneman; Yan Zhang; Yanming Du; Allen B Reitz
Journal:  J Mol Neurosci       Date:  2013-11-26       Impact factor: 3.444

10.  Low Frequency Electrical Stimulation Either Prior to Or after Rapid Kindling Stimulation Inhibits the Kindling-Induced Epileptogenesis.

Authors:  Mostafa Jalilifar; Ali Yadollahpour; Ahmad Ali Moazedi; Zohreh Ghotbeddin
Journal:  Biomed Res Int       Date:  2017-03-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.